Roche has presented positive two-year results from an ongoing study of its spinal muscular atrophy (SMA) treatment Evrysdi ...

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...

Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic ...

Last chance to register for our exclusive webinar, “Why Patient Perspectives Matter: Driving Success in Clinical Trials”!

The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...

• Mtech Access – Powered by Petauri™ are excited to be returning to ISPOR Europe this November. The team will be joined by ...

Johnson & Johnson’s (J&J) Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...